Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer
- 10 February 2015
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 150 (1) , 9-18
Abstract
Receptor kinases Discoidin Domain Receptors (DDRs) 1 and 2 are emerging as new therapeutic targets in breast cancer (BC). However, the expression of DDR proteins during BC progression and their association with BC subtypes remain poorly defined. Herein we report the first comprehensive immunohistochemical analyses of DDR protein expression in a wide range of breast tissues. DDR1 and DDR2 expression was investigated by immunohistochemistry in 218 samples of normal breast (n = 10), ductal carcinoma in situ (DCIS, n = 10), and invasive carcinomas (n = 198), arrayed in tissue microarrays with comprehensive clinical and follow-up information. Staining was evaluated for cell type, subcellular localization, percentage and intensity (scores 1–4), and association with disease subtype and outcome. In normal epithelium and DCIS, DDR1 was highly expressed, while DDR2 was negative in normal epithelium, and in DCIS it localized to cells at the epithelial-stromal interface. Of the 198 invasive carcinomas, DDR1 was high in 87 (44 %) and low in 103 (52 %), and DDR2 was high in 110 (56 %) and low in 87 (44 %). High DDR2 was associated with high tumor grade (P = 0.002), triple-negative subtype (TNBC) (P < 0.0001), and worse survival (P = 0.037). We discovered a novel concordant deregulation of DDR expression, with a DDR1Low/DDR2High profile significantly associated with TNBC, compared to luminal tumors (P = 0.012), and with worse overall survival. In conclusion, DDR2 upregulation occurs in DCIS, before stromal invasion, and may reflect epithelial-stromal cross-talk. A DDR1Low/DDR2High protein profile is associated with TNBC and may identify invasive carcinomas with worse prognosis.Keywords
Funding Information
- National Institutes of Health (R01 CA107469, R01 CA125577, U01 CA154224, R01 CA61986)
This publication has 40 references indexed in Scilit:
- Identification of Type II and III DDR2 InhibitorsJournal of Medicinal Chemistry, 2014
- EZH2 expands breast stem cells through activation of NOTCH1 signalingProceedings of the National Academy of Sciences, 2014
- RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer MetastasisCancer Research, 2013
- Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patientsMedical Oncology, 2013
- Canonical Wnt signaling regulates Slug activity and links epithelial–mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repressionProceedings of the National Academy of Sciences, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Transmembrane Collagen ReceptorsAnnual Review of Cell and Developmental Biology, 2011
- DDR1 triggers epithelial cell differentiation by promoting cell adhesion through stabilization of E-cadherinMolecular Biology of the Cell, 2011
- The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfismEMBO Reports, 2001
- Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breastVirchows Archiv, 1999